TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ALDX

Aldeyra Therapeutics, Inc. - Common Stock

NASDAQ
$0.68
▼ $0.02 (-2.7%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 17 Nov 2026
H $2.53L $0.53-60.2%
$2.53$2.13$1.73$1.33$0.93$0.53$0.68
RSI (14)
Intraday · 15-minBuy+15RSI 55UptrendMACD Bearishfor day-trading context — not advice

Technical signal

Sell-30
RSI (14)43
oversold 30overbought 70
Trend
Downtrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
below
vs 200-day
below
Support
$0.53
Resistance
$0.75
  • Price is below its 50-day average (medium-term weakness).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest · 2026-02-13 → 2026-11-17

Strategy return
-25.9%
Buy & hold
-87.1%
Trades
5
Win rate
0%

$100,000.00 invested would be worth $74,074.76 (-25.9%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Aldeyra Therapeutics, Inc.· Biotechnology

source: yahoo

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Employees
6
Headquarters
Lexington, United States
www.aldeyra.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:▲ Positive3↑ · 1↓ · 4–
  • RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week▲ Positive
    Zacks · 15 Oct 2026
  • Here's Why You Should Add ANRO Stock to Your Portfolio Now— Neutral
    Zacks · 14 Oct 2026
  • Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal▼ Negative
    Zacks · 14 Oct 2026
  • Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
▲ Positive
Zacks · 12 Oct 2026
  • PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know▲ Positive
    Zacks · 12 Oct 2026
  • argenx Meets Primary Endpoint in Phase II Celiac Disease Study— Neutral
    Zacks · 09 Oct 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.